{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:05:25Z","timestamp":1793729125211,"version":"4.6.1"},"reference-count":45,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"unspecified","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["Grant agreement No. 602705."],"award-info":[{"award-number":["Grant agreement No. 602705."]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,5,26]]},"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate cancer (PCa) has been under investigation as a target for antigen-specific immunotherapies in metastatic disease settings for the last two decades leading to a licensure of the first therapeutic cancer vaccine, Sipuleucel-T, in 2010. However, neither Sipuleucel-T nor other experimental PCa vaccines that emerged later induce strong T-cell immunity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this first-in-man study, VANCE, we evaluated a novel vaccination platform based on two replication-deficient viruses, chimpanzee adenovirus (ChAd) and MVA (Modified Vaccinia Ankara), targeting the oncofetal self-antigen 5T4 in early stage PCa. Forty patients, either newly diagnosed with early-stage PCa and scheduled for radical prostatectomy or patients with stable disease on an active surveillance protocol, were recruited to the study to assess the vaccine safety and T-cell immunogenicity. Secondary and exploratory endpoints included immune infiltration into the prostate, prostate-specific antigen (PSA) change, and assessment of phenotype and functionality of antigen-specific T cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The vaccine had an excellent safety profile. Vaccination-induced 5T4-specific T-cell responses were measured in blood by ex vivo IFN-\u03b3 ELISpot and were detected in the majority of patients with a mean level in responders of 198 spot-forming cells per million peripheral blood mononuclear cells. Flow cytometry analysis demonstrated the presence of both CD8+ and\u2009CD4+ polyfunctional 5T4-specific T cells in the circulation. 5T4-reactive tumor-infiltrating lymphocytes were isolated from post-treatment prostate tissue. Some of the patients had a transient PSA rise 2\u20138 weeks following vaccination, possibly indicating an inflammatory response in the target organ.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>An excellent safety profile and T-cell responses elicited in the circulation and also detected in the prostate gland support the evaluation of the ChAdOx1-MVA 5T4 vaccine in efficacy trials. It remains to be seen if this vaccination strategy generates immune responses of sufficient magnitude to mediate clinical efficacy and whether it can be effective in late-stage PCa settings, as a monotherapy in advanced disease or as part of multi-modality PCa therapy. To address these questions, the phase I\/II trial, ADVANCE, is currently recruiting patients with intermediate-risk PCa, and patients with advanced metastatic castration-resistant PCa, to receive this vaccine in combination with nivolumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      The trial was registered with the U.S. National Institutes of Health (NIH) Clinical Trials Registry (ClinicalTrials.gov identifier\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02390063\">NCT02390063<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2020-000928","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T08:07:07Z","timestamp":1593158827000},"page":"e000928","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":47,"title":["Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct02390063","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03815942","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Federica","family":"Cappuccini","sequence":"first","affiliation":[{"name":"Nuffield Department of Medicine, The Jenner Institute, Oxford University, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bryant","sequence":"additional","affiliation":[{"name":"Nuffield Department of Surgical Sciences, Oxford University, Oxford, UK"},{"name":"Department of Urology, Churchill Hospital, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Pollock","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, The Jenner Institute, Oxford University, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Carter","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, The Jenner Institute, Oxford University, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Verrill","sequence":"additional","affiliation":[{"name":"Nuffield Department of Surgical Sciences, Oxford University, Oxford, UK"},{"name":"Oxford NIHR Biomedical Research Centre, Oxford University, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianne","family":"Hollidge","sequence":"additional","affiliation":[{"name":"Nuffield Department of Surgical Sciences, Oxford University, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Poulton","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, The Jenner Institute, Oxford University, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Baker","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, The Jenner Institute, Oxford University, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Mitton","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, The Jenner Institute, Oxford University, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Baines","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, The Jenner Institute, Oxford University, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Meier","sequence":"additional","affiliation":[{"name":"Definiens AG, Munchen, Bayern, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guenter","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Definiens AG, Munchen, Bayern, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Harrop","sequence":"additional","affiliation":[{"name":"Oxford Biomedica Plc, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Protheroe","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"MacPherson","sequence":"additional","affiliation":[{"name":"Department of Radiology, Churchill Hospital, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kennish","sequence":"additional","affiliation":[{"name":"Department of Radiology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selena","family":"Vigano","sequence":"additional","affiliation":[{"name":"Oncology, University Hospital of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro J","family":"Romero","sequence":"additional","affiliation":[{"name":"Oncology, University Hospital of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Evans","sequence":"additional","affiliation":[{"name":"Vaccitech UK Limited, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Catto","sequence":"additional","affiliation":[{"name":"Academic Urology Unit, The University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freddie","family":"Hamdy","sequence":"additional","affiliation":[{"name":"Nuffield Department of Surgical Sciences, Oxford University, Oxford, UK"},{"name":"Department of Urology, Churchill Hospital, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian V S","family":"Hill","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, The Jenner Institute, Oxford University, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3234-3548","authenticated-orcid":false,"given":"Irina","family":"Redchenko","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, The Jenner Institute, Oxford University, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,6,25]]},"reference":[{"key":"2025100303315355000_8.1.e000928.1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent global patterns in prostate cancer incidence and mortality rates","volume":"77","author":"Culp","year":"2020","journal-title":"Eur Urol"},{"key":"2025100303315355000_8.1.e000928.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294"},{"key":"2025100303315355000_8.1.e000928.3","first-page":"137","volume-title":"Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer","volume":"62","author":"Sheikh","year":"2013"},{"key":"2025100303315355000_8.1.e000928.4","first-page":"133141","article-title":"Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer","volume":"2","author":"Gulley","year":"2013","journal-title":"Cancer Immunology Research"},{"key":"2025100303315355000_8.1.e000928.5","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.18.02031","article-title":"Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer","volume":"37","author":"Gulley","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025100303315355000_8.1.e000928.6","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910450132"},{"key":"2025100303315355000_8.1.e000928.7","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1990.20"},{"key":"2025100303315355000_8.1.e000928.8","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1992.375"},{"key":"2025100303315355000_8.1.e000928.9","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1438.1995.05040269.x"},{"key":"2025100303315355000_8.1.e000928.10","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602776"},{"key":"2025100303315355000_8.1.e000928.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.03.008"},{"key":"2025100303315355000_8.1.e000928.12","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3836"},{"key":"2025100303315355000_8.1.e000928.13","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.284"},{"key":"2025100303315355000_8.1.e000928.14","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.248"},{"key":"2025100303315355000_8.1.e000928.15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009185","article-title":"A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory","volume":"6","author":"Swadling","year":"2014","journal-title":"Sci Transl Med"},{"key":"2025100303315355000_8.1.e000928.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411627"},{"key":"2025100303315355000_8.1.e000928.17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208328"},{"key":"2025100303315355000_8.1.e000928.18","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/infdis\/jiy639","article-title":"Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen in healthy adults in the United Kingdom and Senegal","volume":"219","author":"Venkatraman","year":"2019","journal-title":"J Infect Dis"},{"key":"2025100303315355000_8.1.e000928.19","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1831-8"},{"key":"2025100303315355000_8.1.e000928.20","doi-asserted-by":"crossref","first-page":"47474","DOI":"10.18632\/oncotarget.17666","article-title":"5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy","volume":"8","author":"Cappuccini","year":"2017","journal-title":"Oncotarget"},{"key":"2025100303315355000_8.1.e000928.21","doi-asserted-by":"publisher","DOI":"10.4161\/hv.6.10.13144"},{"key":"2025100303315355000_8.1.e000928.22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013940"},{"key":"2025100303315355000_8.1.e000928.23","doi-asserted-by":"crossref","unstructured":"Brieu N , Pauly O , Zimmermann J , et al . Slide-specific models for segmentation of differently stained digital histopathology whole slide images 2016:9784.","DOI":"10.1117\/12.2208620"},{"key":"2025100303315355000_8.1.e000928.24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35501-5","article-title":"Deep semi supervised generative learning for automated tumor proportion scoring on NSCLC tissue needle biopsies","volume":"8","author":"Kapil","year":"2018","journal-title":"Sci Rep"},{"key":"2025100303315355000_8.1.e000928.25","doi-asserted-by":"publisher","DOI":"10.1038\/nm881"},{"key":"2025100303315355000_8.1.e000928.26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078289"},{"key":"2025100303315355000_8.1.e000928.27","first-page":"829","volume-title":"MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients","volume":"60","author":"Harrop","year":"2011"},{"key":"2025100303315355000_8.1.e000928.28","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2012-200923"},{"key":"2025100303315355000_8.1.e000928.29","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-22564-7","article-title":"Tissue phenomics for prognostic biomarker discovery in low- and intermediate-risk prostate cancer","volume":"8","author":"Harder","year":"2018","journal-title":"Sci Rep"},{"key":"2025100303315355000_8.1.e000928.30","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31817deafd"},{"key":"2025100303315355000_8.1.e000928.31","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ebiom.2018.02.011","article-title":"Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus A in healthy adults","volume":"29","author":"Coughlan","year":"2018","journal-title":"EBioMedicine"},{"key":"2025100303315355000_8.1.e000928.32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000655"},{"key":"2025100303315355000_8.1.e000928.33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.9968"},{"key":"2025100303315355000_8.1.e000928.34","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181dda23e"},{"key":"2025100303315355000_8.1.e000928.35","doi-asserted-by":"crossref","first-page":"25586","DOI":"10.18632\/oncotarget.25387","article-title":"Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer","volume":"9","author":"McNeel","year":"2018","journal-title":"Oncotarget"},{"key":"2025100303315355000_8.1.e000928.36","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-015-0068-y"},{"key":"2025100303315355000_8.1.e000928.37","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2012-3439"},{"key":"2025100303315355000_8.1.e000928.38","doi-asserted-by":"crossref","unstructured":"Scurr M et al . Effect of modified vaccinia Ankara\u20135T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer: A randomized clinical trial. JAMA Oncology 2017.","DOI":"10.1001\/jamaoncol.2017.2579"},{"key":"2025100303315355000_8.1.e000928.39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00128"},{"key":"2025100303315355000_8.1.e000928.40","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(94)E0159-2"},{"key":"2025100303315355000_8.1.e000928.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)00152-1"},{"key":"2025100303315355000_8.1.e000928.42","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601943"},{"key":"2025100303315355000_8.1.e000928.43","first-page":"4435","article-title":"Tumour-Infiltrating lymphocytes: a prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy","volume":"25","author":"K\u00e4rj\u00e4","year":"2005","journal-title":"Anticancer Res"},{"key":"2025100303315355000_8.1.e000928.44","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy141"},{"key":"2025100303315355000_8.1.e000928.45","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/bjc.2016.171","article-title":"Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy","volume":"115","author":"Yamamoto","year":"2016","journal-title":"Br J Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-000928","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T10:32:07Z","timestamp":1759487527000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-000928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,6,25]]},"published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1136\/jitc-2020-000928"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-000928","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.03.05.20031500","asserted-by":"object"}]},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}